Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: J Hepatol. 2010 May 27;53(3):460–467. doi: 10.1016/j.jhep.2010.03.019

Table 3.

Viral kinetic and pharmacodynamic parameter estimates.

Patient
No.		 Genotype V0
[ SE]
Log10
(IU/ml)		 t0
[ SE]
(h)		 C
[ SE]
(1/day)		 Ec50a
[SE]		 δa
[ SE]
(1/day)		 n ε7max
(%)		 εmax
(%)
1 * 3 5.9 [0.2] 7.2 [2.9] 6.2 [2.9] 0.25 [0.04] 0.30 [0.02 ] 1.0 97 98
2* 3 5.7 [0.1] 12.0 [3.0] 6.0& 2.97 [0.20] 0.17 [0.01] 2.6 94 99
3 * 3 5.3 [0.1] 13.2 [1.3] 5.5 [0.7] 0.55[0.0 4] 0.14b 1.0 96 SF
6* 3 5.0 [0.4] 6.9 [3.4] 6.0& 0.65 [0.15] 0.13 [0.05] 2.0 99 99
7* 3 5.6 [0.2] 15.0 [3.6] 6.0& 5.74 [2.16] 0.40 [0.04] 1.0 67 72
4* 1 6.8 [0.04] 9.3 [3.6] 2.5 [0.8] 2.0 0.27 1.0 91 93
5 * 1 6.6 [0.1] 15.0 [1.8] 8.5 [2.6] 1.24 [0.25] 0.28 [0.02] 1.2 9 5 97
Median
(IQR)		 5.7 (1.3) 12.0 (7.8) 6.0 (0.7) 1.6 (3.1) 0.28 (0.17) 1.1 (1.2) 95 (13) 98 (11)
8 3 5.7 [0.03] 4.0 [1.2] 4.8 [0.9] 1.1 0.18 1.0 86 91
9 3 6.1 [0.1] 13.8 [2.1] 5.9 [1.2] 1.63 [0. 18] 0.24 [0.04] 1.0 8 7 89
13 3 6.1 [0.1] 10.9 [1.7] 5.8 [0.6] 1.4 0.26 1.0 9 2 94
10 1 5.2 [0.1] 17.5 [1.8] 6.0& 13.25 [3.15] 0.09 [0.01] 1.0 4 7 58
11 1 5.7 [0.03] 14.0 [1.9] 3.8 [0.9] 4.63 [0.54] 0.12 [0.01] 2.0 86 93
12 1 5.2 [0.1] 7.9 [4.2] 6.0& 17.12 [4.86] 0.10 [0.01] 1.0 43 54
14 1 6.5 [0.1] 2 7.8 [1.9] 6.0& 13.4 0.11 1.0 47 62
15 1 5.7 [0.1] 1 0.1 [1.7] 6.0 [1.6] 3.18 [0. 39] 0.07 [0.03] 1.3 72 SF
16 1 6.4 [0.2] 7.9 [5.1] 2.8 [1.1] 0.8 0.11 1.0 95 96
17 1 6.4 [0.2] 1 8.0 [2.4] 8.1 [1.1] 2.3 0.11 1.0 86 89
18** 1 6.5 NF NF NF NF NF NF NF
19**, $ 1 6.4 NF NF NF NF NF NF NF
20$ 1 6.8 [0.2] 0 [4.4] 6.0& 3.6 0.15 1.0 76 84
21$ 1 6.1 [0.04] 7.7 [0.6] 8.2 [2.4] NF NF NF NF NF
Median
(IQR)		 6.1 (1.0) 10.9 (9.9) 6.0 (0.7) 3.0 (12.0) 0.12 (0.09) 1.0 (0.2) 86 (41) 89 (32)
p value NS NS 0.085 0.011 NS 0.011 0.022
*

SVRs;

**

Null responders during 12 weeks of treatment;

&

due to large standard error [SE] we fixed c = 6 day−1 as previously estimated[14];

$

detectable HCV RNA at the end of treatment (week 48);

a

parameters that include SE for δ or EC50 were estimated using Eq. S2 (see Methods and Supplementary Material), the remaining cases were estimated by a mathematical model that includes hepatocytes proliferation, see Eq. S1 and Table S1 in Supplementary Material;

b

due to large SE the decay rate was directly estimated by linear regression from day 7 to day 15; SD, standard deviation; NF, model cannot not be fitted to the data as explained in Methods; SF, since interferon-α declined from day 15 model fit was performed until that time.